Literature DB >> 1700674

Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.

N J Struyf1, H W Snoeck, C H Bridts, L S De Clerck, W J Stevens.   

Abstract

Natural killer (NK) cell activity and its stimulation by interferons (IFNs) and interleukin-2 (IL-2) are diminished in Sjögren's syndrome and systemic lupus erythematosus (SLE). Serum samples of these patients often contain circulating immune complexes, which may influence NK cell activity. Sixteen patients with Sjögren's syndrome (14/16 immune complex positive), 14 with SLE (9/14 immune complex positive), and 11 controls (immune complex negative) were studied. Mononuclear cells collected from a Percoll gradient were preincubated with recombinant IFN-alpha (rIFN-alpha) (100 U/ml), rIFN-gamma (1000 U/ml), rIL-2 (100 U/ml), or without cytokine. Natural killer cell activity was determined by incubating the mononuclear cells with carboxyfluorescein labelled K562 cells, and the percentage decrease of fluorescence was measured on an FACS Analyzer. In patients with Sjögren's syndrome and SLE NK cell activity and the numbers of cells expressing the NK cell associated antigens CD16 and Leu7 were diminished compared with the controls. Interleukin-2 stimulated NK cell activity significantly in comparison with the non-stimulated value in all studied groups, whereas IFN-gamma only stimulated NK cell activity in both patient groups and IFN-alpha only in patients with Sjögren's syndrome. There was no correlation between NK cell activity, with or without stimulation, and the immune complex concentrations. It is concluded that NK cell activity is decreased in Sjögren's syndrome and SLE and that it may be partially restored by IL-2 and IFN-gamma in both diseases, and by IFN-alpha in Sjögren's syndrome. The decrease of NK cell activity did not correlate with immune complex concentrations; on the other hand, decreased numbers of NK cells (CD16+ or Leu7+) and of cytokine concentrations might be important in the impaired NK cell activity in both diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700674      PMCID: PMC1004205          DOI: 10.1136/ard.49.9.690

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  Interleukin 2 receptors and responsiveness to recombinant human interleukin 2 in patients with systemic lupus erythematosus.

Authors:  S Lakhanpal; B S Handwerger
Journal:  Mayo Clin Proc       Date:  1987-01       Impact factor: 7.616

3.  Serum levels of interferons in patients with systemic lupus erythematosus.

Authors:  T Kim; Y Kanayama; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

4.  Selective impairment of alpha-interferon-mediated natural killer augmentation in Sjögren's syndrome: differential effects of alpha-interferon, gamma-interferon, and interleukin 2 on cytolytic activity.

Authors:  A Takeda; N Minato; S Kano
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

5.  A fluorescence NK assay using flow cytometry.

Authors:  K McGinnes; G Chapman; R Marks; R Penny
Journal:  J Immunol Methods       Date:  1986-01-22       Impact factor: 2.303

6.  Circulating natural killer cells in Sjögren's syndrome.

Authors:  Y Ichikawa; M Yoshida; M Takaya; M Uchiyama; H Shimizu; S Arimori
Journal:  Arthritis Rheum       Date:  1985-02

7.  Partial purification and characterization of systemic lupus erythematosus derived factors that suppress production of interleukin-2.

Authors:  M Linker-Israeli; N Casteel
Journal:  J Rheumatol       Date:  1988-06       Impact factor: 4.666

8.  Natural killer cell activity in the systemic connective tissue diseases.

Authors:  R Gonzalez-Amaro; J Alcocer-Varela; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1988-08       Impact factor: 4.666

9.  Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.

Authors:  B K Pedersen; P Oxholm; R Manthorpe; V Andersen
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

10.  Role of IgM-rheumatoid factor interference in the determination of total serum IgE and IgE-containing circulating immune complexes.

Authors:  L S De Clerck; P L Gigase; C H Bridts; W J Stevens
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

View more
  11 in total

1.  Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.

Authors:  M R J Green; A S M Kennell; M J Larche; M H Seifert; D A Isenberg; M R Salaman
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 2.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

Review 3.  Dry eye disease: an immune-mediated ocular surface disorder.

Authors:  William Stevenson; Sunil K Chauhan; Reza Dana
Journal:  Arch Ophthalmol       Date:  2012-01

Review 4.  Contributions of Major Cell Populations to Sjögren's Syndrome.

Authors:  Richard Witas; Shivai Gupta; Cuong Q Nguyen
Journal:  J Clin Med       Date:  2020-09-22       Impact factor: 4.241

Review 5.  The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy.

Authors:  Chris Fraker; Allison L Bayer
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

6.  NK cells dysfunction in systemic lupus erythematosus: relation to disease activity.

Authors:  Ana Henriques; Luís Teixeira; Luís Inês; Tiago Carvalheiro; Ana Gonçalves; António Martinho; Maria Luísa Pais; José António Pereira da Silva; Artur Paiva
Journal:  Clin Rheumatol       Date:  2013-02-02       Impact factor: 2.980

7.  Immune complexome analysis reveals the presence of immune complexes and identifies disease-specific immune complex antigens in saliva samples from patients with Sjögren's syndrome.

Authors:  K Yamane; H Nakamura; M Hamasaki; Y Minei; N Aibara; T Shimizu; A Kawakami; M Nakashima; N Kuroda; K Ohyama
Journal:  Clin Exp Immunol       Date:  2021-02-22       Impact factor: 4.330

8.  Distribution of Peripheral Lymphocyte Populations in Primary Sjögren's Syndrome Patients.

Authors:  Gintaras Sudzius; Diana Mieliauskaite; Almantas Siaurys; Rita Viliene; Irena Butrimiene; Dainius Characiejus; Irena Dumalakiene
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

Review 9.  Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease.

Authors:  Carolyn M Nielsen; Matthew J White; Martin R Goodier; Eleanor M Riley
Journal:  Front Immunol       Date:  2013-12-09       Impact factor: 7.561

10.  The Role of Long Non-coding RNAs in the Pathogenesis of RA, SLE, and SS.

Authors:  Yunzhen Gao; Shasha Li; Zhongjian Zhang; Xinhua Yu; Junfeng Zheng
Journal:  Front Med (Lausanne)       Date:  2018-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.